License and Commercialisation Agreement in AUS/NZ for R327G
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Under this agreement, Arrotex will have exclusive rights to commercialize the product, while Recce will remain the exclusive manufacturer and supplier. This partnership aims to address the unmet medical needs associated with diabetic foot infections, which can lead to severe complications if untreated.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Independent Review of Indonesian Phase 3 R327G Trial Data
- Notification regarding unquoted securities - RCE
- Amendments to Debt Facility with Avenue Capital Group
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - RCE
Later from Recce Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - RCE
- Cleansing Notice
- Options Prospectus
- Retirement of Mr Alistair McKeough as Non-Executive Director
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals